Effect of long-stranded non-coding RNA-BANCR on the progression of thyroid papillary carcinoma and its mechanism

被引:1
作者
Yu, Jiayi [1 ]
Hong, Kai [2 ,3 ]
Yao, Lingli [4 ]
Shi, Dongbo [4 ]
Zhang, Jiabo [4 ]
机构
[1] Ningbo Univ, Med Sch, Ningbo 315211, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 4, Sch Med, Ctr Metab Med, Yiwu 322000, Peoples R China
[3] Zhejiang Univ, Int Inst Med, Int Sch Med, Yiwu 322000, Peoples R China
[4] Ningbo Univ, Dept Breast Surg, Affiliated Hosp 1, Ningbo 315010, Zhejiang, Peoples R China
关键词
Long non-coding RNA; BANCR; Papillary thyroid carcinoma; Hashimoto's thyroiditis; P53; CANCER; BRAF;
D O I
10.1007/s12672-025-01755-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective This study aims to investigate the role of BRAF-activated long non-coding RNA (BANCR) in papillary thyroid carcinoma (PTC) progression and its association with clinical and molecular characteristics. Methods Sixteen PTC patients were stratified into four groups (PTC, HT, HT-LNM, and PTC-LNM) based on cervical lymph node metastasis and concurrent Hashimoto's thyroiditis (HT) to explore BANCR expression and its relationship with immune-related factors and tumor microenvironment (TME). Functional assays, including Transwell invasion, colony formation, and CCK8 were performed to evaluate the biological effects of BANCR in PTC cell lines. Bioinformatics analysis further identified BANCR-related pathways and clinical relevance. Results BANCR expression was significantly reduced in PTC tissues compared to normal thyroid tissues and was inversely correlated with tumor grade, lymph node metastasis, and T stage. Overexpression of BANCR in PTC cell lines inhibited proliferation, invasion and migration. Bioinformatics analysis demonstrated significant associations between BANCR and immune cell infiltration, immune-related genes, and stromal scores. Conclusions BANCR acts as a tumor suppressor in PTC, suppressing tumor growth and metastasis. These findings provide insights into BANCR's potential as a prognostic marker and therapeutic target in PTC.
引用
收藏
页数:11
相关论文
共 17 条
[1]  
Ahmad Aamir, 2016, Noncoding RNA Res, V1, P1, DOI [10.1016/j.ncrna.2016.12.001, 10.1016/j.ncrna.2016.12.001]
[2]   Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response [J].
Cazzalini, Ornella ;
Scovassi, A. Ivana ;
Savio, Monica ;
Stivala, Lucia A. ;
Prosperi, Ennio .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2010, 704 (1-3) :12-20
[3]   Cyclins and cell cycle checkpoints [J].
Johnson, DG ;
Walker, CL .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :295-312
[4]   BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer [J].
Liao, Tian ;
Qu, Ning ;
Shi, Rong-Liang ;
Guo, Kai ;
Ma, Ben ;
Cao, Yi-Ming ;
Xiang, Jun ;
Lu, Zhong-Wu ;
Zhu, Yong-Xue ;
Li, Duan-Shu ;
Ji, Qing-Hai .
ONCOTARGET, 2017, 8 (01) :238-247
[5]   Mdm2 and MdmX: Partners in p53 Destruction [J].
Manfredi, James J. .
CANCER RESEARCH, 2021, 81 (07) :1633-1634
[6]   Anaplastic thyroid cancer [J].
Neff, Ryan L. ;
Farrar, William B. ;
Kloos, Richard T. ;
Burman, Kenneth D. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2008, 37 (02) :525-+
[7]   LncRNA-mediated regulation of cell signaling in cancer [J].
Peng, W-X ;
Koirala, P. ;
Mo, Y-Y .
ONCOGENE, 2017, 36 (41) :5661-5667
[8]   Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations [J].
Quiros, RM ;
Ding, HG ;
Gattuso, P ;
Prinz, RA ;
Xu, XL .
CANCER, 2005, 103 (11) :2261-2268
[9]   Low frequency of p53 mutations in human thyroid tumors; p53 and Ras mutation in two out of fifty-six thyroid tumours [J].
Salvatore, D ;
Celetti, A ;
Fabien, N ;
Paulin, C ;
Martelli, ML ;
Battaglia, C ;
Califano, D ;
Monaco, C ;
Viglietto, G ;
Santoro, M ;
Fusco, A .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1996, 134 (02) :177-183
[10]   Active surveillance of low-risk papillary thyroid cancer: A meta-analysis [J].
Saravana-Bawan, Bianka ;
Bajwa, Amandeep ;
Paterson, John ;
McMullen, Todd .
SURGERY, 2020, 167 (01) :46-54